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The anti-CD20 antibody ocrelizumab, approved for treatment of
multiple sclerosis, leads to rapid elimination of B cells from the
blood. The extent of B cell depletion and kinetics of their recovery
in different immune compartments is largely unknown. Here, we
studied how anti-CD20 treatment influences B cells in bone
marrow, blood, lymph nodes, and spleen in models of experimental
autoimmune encephalomyelitis (EAE). Anti-CD20 reduced mature B
cells in all compartments examined, although a subpopulation of
antigen-experienced B cells persisted in splenic follicles. Upon treat-
ment cessation, CD20+ B cells simultaneously repopulated in bone
marrow and spleen before their reappearance in blood. In EAE in-
duced by native myelin oligodendrocyte glycoprotein (MOG), a model
in which B cells are activated, B cell recovery was characterized by
expansion of mature, differentiated cells containing a high frequency
of myelin-reactive B cells with restricted B cell receptor gene diversity.
Those B cells served as efficient antigen-presenting cells (APCs) for
activation of myelin-specific T cells. In MOG peptide-induced EAE, a
purely T cell-mediated model that does not require B cells, in contrast,
reconstituting B cells exhibited a naive phenotype without efficient
APC capacity. Our results demonstrate that distinct subpopulations of
B cells differ in their sensitivity to anti-CD20 treatment and suggest
that differentiated B cells persisting in secondary lymphoid organs
contribute to the recovering B cell pool.
multiple sclerosis | experimental autoimmune encephalomyelitis |
secondary lymphoid organ | anti-CD20 | B cell recovery
Monoclonal antibodies against CD20 deplete immature andmature B cells and spare plasma cells and hematopoietic
stem cells as a result of their lack of CD20 expression. Rituximab
was the first anti-CD20 antibody to be tested in clinical multiple
sclerosis (MS) trials, which revealed a rapid decline in the devel-
opment of new CNS lesions in patients with relapsing-remitting
(RR) MS (1, 2). In primary progressive (PP) MS, a subgroup of
younger patients with ongoing CNS lesion formation experienced a
slowing in disease progression (3). All available case series indicate
that rituximab is also effective and safe in patients with neuro-
myelitis optica (NMO) and NMO spectrum disorders (4–6). Testing
rituximab’s further humanized successor ocrelizumab confirmed a
substantial reduction in the frequency of clinical relapses and CNS
lesion formation in RR-MS (7, 8) and a significantly decelerated
accumulation of disability in patients with PP-MS (9). Based on
these phase III clinical trial findings, ocrelizumab has been approved
recently for both MS indications.
Notwithstanding this encouraging development, several
mechanistic questions remain to be addressed. To date, it is
largely unknown to what extent B cell-rich compartments, such as
bone marrow, spleen, and lymph nodes, are depleted by anti-CD20
treatment and how they are repopulated with B cells after cessation
of anti-CD20 treatment. Moreover, it is crucial to clarify in which
functional status B cells reappear after their transient anti-CD20–
mediated extinction and to learn which factors shape the reemerging
B cell phenotype. This question is of tremendous clinical relevance, as
it determines whether patients need to be continuously depleted of B
cells, which may significantly increase the long-term safety risk over
time. To approach thesemechanistic questions, we investigated de- and
repletion of B cells upon transient anti-CD20 treatment in murine
model systems with access to all tissues and compartments. To model
different functional aspects, we used naïve mice, as well as two models
of experimental autoimmune encephalomyelitis (EAE), one in which
activated B cells contribute to EAE development and one in which B
cells are not activated in an antigen-specific manner.
Results
Anti-CD20 Efficiently Depletes Peripheral Immature and Mature B Cells,
Whereas a Subset of CD20+ B Cells Persists in Secondary Lymphoid
Organs. We first investigated the extent of B cell depletion upon
systemic application of murine anti-CD20 in the bone marrow,
spleen, lymph nodes, and blood of naïve mice. As indicated in Fig.
1A and SI Appendix, Fig. S1A, three weekly injections of 0.2 mg
anti-CD20 significantly reduced the frequency of B220+/CD19+ B
cells in all compartments. The depicted B cell frequency concomi-
tantly represents the maximum effect of anti-CD20 treatment, as
further injections or higher doses of anti-CD20 exerted no addi-
tional effect. The highest B cell depletion efficacy was achieved in
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the blood, where B cells were virtually absent after anti-CD20
treatment. The overall weakest reduction of B220+/CD19+ B cells
was observed in the bone marrow. Although CD20+ B cells were
efficiently depleted, a large population of CD20− B cell precursors
and plasma cells persisted in this compartment (SI Appendix, Fig.
S1B, Lower). In contrast, virtually all B cells remaining present in
secondary lymphoid organs after anti-CD20 treatment proved to be
CD20-positive (SI Appendix, Fig. S1B, Lower), with an enlarged
proportion expressing CD27, an activation marker that murine B
cells acquire when entering the germinal center reaction (10) (Fig.
1B and SI Appendix, Fig. S1C). In line with this finding, histologic
examination revealed a predominant persistence of B cells in areas
of follicular structures (Fig. 1C).
B Cell Repletion Starts in the Bone Marrow and the Spleen, Whereas B
Cells Reappear in Lymph Nodes and Blood Substantially Thereafter.
To investigate when and where B cells reappear after systemic B
cell depletion, the frequency of B220+CD19+ B cells in the bone
marrow, spleen, lymph nodes, and blood was assessed weekly
after a full course of three anti-CD20 injections in naïve mice. As
shown in Fig. 2, 6 wk after the last anti-CD20 injection, the B cell
frequency started to increase in the bone marrow as well as in the
spleen. By wk 9, in both of these compartments, B cell numbers
were fully restored. In contrast, B cells reappeared slowly and
steadily in lymph nodes and blood, with a substantial delay
compared with bone marrow and spleen. Accordingly, full B cell
repletion was not achieved in blood and lymph nodes before wk 12
after the last anti-CD20 dosing.
B Cell Repletion Kinetic Accelerates in the Context of an Active
Immunization, Whereas the Clinical Effect of B Cell De- and Repletion
Depends on the EAE Model Used. Next, we assessed B cell depletion
and recovery in the context of active EAE. To best reflect distinct
aspects of B cell function, we used two EAE models with differential
B cell involvement: (i) myelin oligodendrocyte glycoprotein (MOG)
protein1–117-induced EAE, a model in which activated, antigen-
specific B cells contribute as potent APCs, providers of proin-
flammatory cytokines and source of antibody-producing plasma cells;
and (ii) T cell-mediatedMOG peptide35–55-induced EAE, in which B
cells are not activated by the immunogen (11) (SI Appendix, Fig. S2).
To correct for changes in the relative abundance of B cells
caused by the active immunization, we compared the frequency
of reappearing B cells to nondepleted, isotype-treated control
mice at identical time points after immunization. Compared with
naïve mice (Fig. 2), B cell repletion occurred overall faster and
more simultaneously throughout the various compartments in
the context of an active immunization (Fig. 3 A and B, Upper).
The fastest restoration occurred in MOG protein1–117 EAE, and
B cell frequencies even exceeded the level of nondepleted con-
trols in most compartments (Fig. 3A, Upper). Analyzing the or-
igin of reoccurring B cells, we observed that, 8 wk after the last
anti-CD20 treatment, B cells proliferated in spleen and lymph
nodes (Fig. 3 C and D and SI Appendix, Fig. S3 A and B), sug-
gesting that, early in the process of repletion, persisting B cells
expanded locally in secondary lymphoid organs.
We also evaluated the clinical effect of B cell de- and repletion
in both models (Fig. 3 A and B, Lower). Preventive anti-CD20
treatment reduced the severity of MOG protein1–117-induced
EAE, as expected by the pathogenic involvement of B cells in
this model (12). In contrast, preventive depletion of B cells in
MOG peptide35–55-induced disease significantly exacerbated its
course (Fig. 3 A and B, Lower). Inversely mirroring the clinical
effect of anti-CD20 treatment, reappearance of B cells was as-
sociated with gradual clinical worsening in MOG protein EAE,
whereas repletion of B cells in purely T cell-mediated EAE damp-
ened the preceding disease exacerbation mediated by anti-CD20
Fig. 1. Characterization of remaining B cells after repetitive anti-CD20
treatment. Mice were treated weekly with anti-CD20 (α-CD20) or isotype
antibodies for three consecutive weeks. (A) Frequency of B cells in blood,
spleen, inguinal lymph nodes, and bone marrow assessed by flow cytometry
using antibodies against CD19 and B220 1 wk after the last injection. Shown
is the mean percentage of B cells ± SEM, pregated on intact cells (n = 3 mice
per group; *P < 0.05 and ***P < 0.001). (B) Expression of CD27 on B cells in
blood, spleen, inguinal lymph nodes, and bone marrow determined by flow
cytometry. Shown is the mean percentage of CD27+ cells ± SEM, pregated on
CD19+ B220+ cells (n = 3 mice per group; ***P < 0.001). (C) Representative
spleen sections stained for B220 by immunohistochemistry. (Scale bars:
overview, 200 μm; inlay, 50 μm.)
Fig. 2. Kinetic of B cell reappearance in naïve mice after anti-CD20 with-
drawal. C57BL/6 mice were treated weekly with anti-CD20 or isotype anti-
bodies for three consecutive weeks. B cell frequencies in blood, spleen,
inguinal lymph nodes, and bone marrow were determined by flow cytom-
etry at the indicted time points by using antibodies against CD19 and B220.
Shown is the mean percentage of B cells (pregated on all leukocytes) in mice
previously treated with anti-CD20 normalized to age- and course-matched
isotype-treated controls (n = 1–3 mice per time point).
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treatment (Fig. 3 A and B, Lower). These findings suggest that the
functional outcome of anti-CD20 in treatment of experimental CNS
autoimmune disease is determined by the extent of pathogenic B cell
involvement and indicate that the absence of regulatory and patho-
genic B cell properties upon anti-CD20 treatment is transient.
Analyzing CNS histology at the end of the study, the clinically
deteriorating effect of transient B cell depletion in mice immunized
with MOG peptide35–55 was still reflected by enhanced cellular in-
filtration and demyelination of the spinal cord (Fig. 4, Right). In
contrast, in mice immunized with MOG protein1–117, no difference
regarding demyelination and inflammation could be observed any-
more (Fig. 4 A and B, Left). This was associated with a fully restored
number of B cells, a slight increase in the number of T cells (Fig. 4 D
and E, Left), and an accentuated increase in the number of activated
MAC-3+ myeloid cells (Fig. 4C, Left).
B Cells Returning in an Activating Milieu Reveal a Shift Toward Highly
Differentiated Phenotypes Containing an Elevated Frequency of
Autoreactive B Cells. Based on these results, we hypothesized that B
cells can generally reappear with predominantly pathogenic or
beneficial properties depending on the milieu in which they repo-
pulate. We thus determined the phenotype and composition of
reappearing B cells in mice with MOG protein1–117 or MOG pep-
tide35–55 EAE. For simplicity, we divided B cells into four virtually
exclusive categories: CD23+ B cells, which represent the vast ma-
jority of transitional and follicular B cells; antigen-experienced B
cells expressing CD27; and differentiated plasma blasts and plasma
cells expressing CD138. Cells expressing none of these markers were
defined as “others.” As depicted in Fig. 5A, isotype-treated mice
with MOG protein1–117 and MOG peptide35–55 EAE showed a
comparable distribution of CD23+, CD27+, and CD138+ cells.
Thereafter, we analyzed the distribution of these B cell subgroups in
the process of repletion. To our surprise, 8 wk after anti-CD20
treatment, both models revealed a relative expansion of activated
CD27+ B cells; in mice immunized with MOG protein1–117, 72.2%
of splenic B cells expressed CD27 and CD23+ cells were virtually
absent (0.8%), whereas, in MOG peptide35–55 EAE, still 21.7% of
all reappearing B cells were found to be CD23+. Although the ex-
pression of CD69 was increased on CD19+ cells in both models,
CD80 was up-regulated only in MOG protein1–117-immunized mice.
To further characterize reappearing B cells, we analyzed their
B cell receptor (BCR) repertoire by deep immune repertoire
sequencing. B cells reappearing in secondary lymphoid organs
8 wk after cessation of anti-CD20 treatment had a reduced di-
versity of their B cell repertoire compared with matched control
mice (Fig. 5B) per the Shannon diversity index, which, in our
setting, represents the diversity of the rearranged Ig variable
region heavy-chain mRNA. Specifically, the IgM repertoire in
lymph nodes was less diverse in previously B cell-depleted mice
(Fig. 5B), and the equivalent alteration could be detected in the
spleen in class-switched IgG-positive B cells (SI Appendix, Fig. S4
A and B). Interestingly, a reduced BCR repertoire diversity was
observed in both models, EAE induced with MOG protein1–117
and MOG peptide35–55, but reached statistical significance only
in MOG protein1–117 EAE. These findings suggest that, after
anti-CD20 treatment, B cells reconstitute from a rather limited
pool of surviving B cells and/or B cell progenitors.
Importantly, we compared these observations at week 8 to a
time point at which the overall frequency of B cells in the spleen
was further restored, 12 wk after anti-CD20 treatment. Whereas,
in MOG peptide35–55 EAE, the relative shift toward a more ex-
perienced B cell phenotype had been completely overwritten, the
frequency of antigen-experienced CD27+ B cells remained ele-
vated in MOG protein1–117-immunized mice (SI Appendix, Fig. S4
C and D). These findings indicate that, although enhanced acti-
vation of B cells during repletion is transient, B cell removal had
lastingly altered their composition toward more mature and dif-
ferentiated phenotypes in MOG protein1–117-immunized mice.
B Cells Reappear with an Enhanced Antigen-Presenting Function in
MOG Protein1–117, but Not in MOG Peptide35–55, EAE. To investigate
whether these phenotypical changes translated into enhanced
pathogenic properties of reappearing B cells in MOG protein1–117
EAE, we next investigated their capacity to act as APCs (Fig.
6A). In light of the phenotypical changes described here earlier,
these assays were performed at wk 8 and 12 after the last anti-
CD20 dosing. As indicated in Fig. 6 B and C, at both time points,
T cell proliferation was substantially enhanced when B cells
reappearing in the context of MOG protein1–117 immunization
acted as APCs, whereas this gain of APC function was not ob-
served in MOG peptide35–55 EAE. As the APC capacity of B
cells is strongly enhanced when they recognize the antigen to be
presented via their BCRs, we next evaluated to what extent B
cells isolated from formerly B cell-depleted, MOG protein1–117-
immunized mice were capable of binding fluorescence-labeled
MOG protein1–117. Compared with matched nondepleted con-
trol donors, a significantly higher frequency of B cells reap-
pearing after anti-CD20 treatment recognized and bound MOG
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Fig. 3. Kinetic of reappearing B cells in transiently B cell-depleted mice im-
munized with MOG protein1–117 or MOG peptide35–55 and its impact on the
EAE course. C57BL/6 mice were treated with anti-CD20 (α-CD20) or isotype
antibodies for three consecutive weeks, followed by immunization with (A)
MOG protein1–117 or (B) MOG peptide35–55 as indicated. B cell frequencies in
blood, spleen, inguinal lymph nodes, and bone marrow were determined by
flow cytometry at the indicted time points by using antibodies against CD19
and B220 (Upper). Shown is the mean percentage of B cells in mice previously
treated with anti-CD20 normalized to age- and course-matched isotype-
treated controls (n = 1–2 mice per time point). Mean clinical score ± SEM of
α-CD20 and isotype-treated mice at indicated time points (Lower; n = 5–8 mice
per group; *P < 0.05). Eight weeks after the last anti-CD20/isotype treatment,
mice immunized with (C) MOG protein1–117 or (D) MOG peptide35–55 received a
single i.p. injection of BrdU. Twenty-four hours later, mice were killed and B
cells in spleen, inguinal lymph nodes, and bone marrow were analyzed for
BrdU incorporation. Shown is the mean percentage ± SEM of BrdU+ cells
pregated on CD19+ B cells (n = 3 mice per group; *P < 0.05).
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protein (Fig. 6D), indicating that this autoreactive population
had expanded in the process of repletion.
Discussion
In this study, we investigated the clinical and immunological
effects of systemic anti-CD20 treatment in experimental CNS
autoimmunity with a particular focus on the circumstances of B
cell repletion after cessation of therapy. Treating different mu-
rine models with anti-CD20, we first confirmed that the de-
pletion of peripherally activated B cells in MOG protein1–117-
induced EAE ameliorated its severity, which is mainly attributed
to abrogation of potent B cell APC function in this model (12, 13).
Of note, transient B cell depletion in this setting was associated
with a significant increase in the frequency of activated macro-
phages and/or microglia within the CNS. In parallel to this pre-
clinical observation, we had reported earlier that, in patients with
NMO and MS treated with anti-CD20, peripheral monocytes
show signs of an enhanced activation status and proinflammatory
differentiation (14), suggesting that B cells physiologically control
the activity of myeloid cells and that this desirable B cell property
is abolished by anti-CD20 treatment (15). The possible clinical
relevance of this regulatory axis between B cells and cells of myeloid
origin is highlighted by a recent case report in which a patient with
NMO depleted of B and T cells by administration of alemtuzumab
died after 20 mo of continuous deterioration, which was associated
with a massive CNS infiltration of monocytes (16). In light of the
emerging concept that cells of myeloid origin play a central role in
maintaining CNS residual inflammation, our observation of an
unleashed activity of CNS myeloid cells may furthermore indicate
that, despite its outstanding ability to control de novo emerging
focal CNS inflammation, anti-CD20–mediated B cell depletion may
not positively influence self-sustained CNS-intrinsic inflammation,
the projected core process of chronic progression (17).
Analyzing the effect of anti-CD20 treatment on compartments
other than blood, we observed that systemic anti-CD20 reduced
the frequency of B cells in bone marrow, lymph nodes, and the
spleen, whereas a remarkable number of cells remained detect-
able within follicular structures. These B cells were not only
found to be CD20+, but also expressed the maturation marker
CD27 (10), suggesting that a fraction of antigen-experienced B
cells had escaped from systemic anti-CD20 treatment. A parallel
observation was reported in patients with Sjögren’s syndrome,
in whom persisting memory B cells could be detected in salivary
glands even after 2 y of consecutive rituximab treatment (18). Along
the same lines, anti-CD20 treatment of patients with rheumatoid
arthritis enriched the relative abundance of memory B cells that
coexpressed the proliferation marker Ki-67 (19), confirming that
memory B cells can escape systemic anti-CD20–mediated B cell
depletion, presumably in organs other than the blood.
Investigating when and in which order B cells repopulated
peripheral immune compartments, we found that B cell numbers
recovered detectably in the bone marrow starting 6 wk after the
last anti-CD20 treatment, which likely reflects the physiological
maturation of CD20− precursor cells in this organ. In addition,
CD20+ B cells rapidly expanded in the spleen, with a subsequent
kinetic indistinguishable from the bone marrow, suggesting a
Fig. 4. Histologic evaluation of transiently B cell-
depleted mice immunized with MOG protein1–117
or MOG peptide35–55. C57BL/6 mice were treated
with anti-CD20 (α-CD20) or isotype antibodies
for 3 wk, followed by immunization with MOG
protein1–117 or MOG peptide35–55 as indicated.
Fourteen weeks after the last α-CD20/isotype treat-
ment, mice were killed, and demyelination [Luxol fast
blue/periodic acid–Schiff (LFB/PAS)], overall inflam-
mation (H&E), and number of infiltrating immune
cells (immunohistochemistry) were determined in
spinal cord sections (n = 4–7 mice per group). (A)
Representative sections (Left) and group median
percentage of demyelinated white matter area (LFB/
PAS; Right) and (B) representative sections (Left) and
median group score of spinal cord inflammation (HE;
Right), determined as follows: 1, slight inflammation;
2, moderate inflammation; 3, strong inflammation.
Representative sections (Left) and median numbers
(Right) of (C) MAC-3, (D) CD3, and (E) B220 immu-
nopositive cells per square millimeter of spinal cord.
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simultaneous recovery of B cells in both compartments. In con-
trast, blood was repopulated substantially thereafter, presumably
because of a secondary distribution of B cells from bone marrow
and spleen into this compartment. It is conceivable that our results
in mice reflect de- and repletion of B cells in the equivalent com-
partments in patients with MS treated systemically with rituximab
(20) or ocrelizumab (7); in regard to dosing, patients receive ∼8–12
mg/kg of the respective anti-CD20 antibody, and mice were treated
with 10 mg/kg of murine anti-CD20 in the present study. Our ex-
perimental findings may therefore question whether monitoring
circulating blood B cells is truly reflective of functional B cell re-
covery in patients (21, 22).
One central finding of the present study is that the circum-
stances under which B cells replete determine the immunological
and possibly clinical long-term outcome of noncontinuous B cell
depletion. Characterizing and comparing reappearing B cells in
different models revealed that antigen-specific stimulation can
shape the evolving B cell phenotype in a pathogenic manner as
the emerging post–anti-CD20 population showed a substantial
increase in the frequency of differentiated, antigen-experienced
B cells with a reduced BCR diversity. Functionally, these
activation-related changes translated into an enhanced APC
function of B cells. Although the BCR repertoire also tended to
be less diverse in previously anti-CD20–treated mice immunized
with MOG peptide35–55, B cells returned with an approximately
unchanged phenotype, and, most importantly, with an unaltered
capacity to act as APCs in this model. It may therefore be central
to anticipate in which milieu B cells regrow after their thera-
peutic removal. In this regard, it has been reported that, in pa-
tients with type 1 diabetes, the autoimmune B cell response
against insulin-producing β-cells in the pancreas reappears im-
mediately after transient B cell depletion with an expansion of
existing, as well as newly emerging, B cell clones (23). In ritux-
imab treatment of patients with anti–myelin-associated glyco-
protein neuropathy, clinical responders and nonresponders can
be distinguished by the persistence and expansion of clonal IgM
Fig. 5. Phenotype and BCR diversity of reappearing B cells 8 wk after anti-
CD20 withdrawal in mice immunized with MOG protein1–117 or MOG pep-
tide35–55. C57BL/6 mice were treated with anti-CD20 (α-CD20) or isotype
antibodies for 3 wk, followed by immunization with MOG protein1–117 or
MOG peptide35–55 as indicated. (A) Eight weeks after the last anti-CD20/
isotype treatment, differentiation of CD19+ cells was analyzed in spleen by
flow cytometry using antibodies against CD23 (naïve B cells), CD27 (activated
B cells), and CD138 (plasma blasts and cells); B cells expressing none of these
markers are defined as “others.” Shown are the respective B cell subtypes in
percentages of all CD19+ cells (Upper). B cell activation was determined by
using antibodies against CD69 and CD80. Shown are the respective mean
fluorescence intensities (MFIs) of pregated CD19+ cells (Lower; n = 2 mice per
group). (B) Eight weeks after the last B cell-depleting treatment, BCR di-
versity was assessed in lymph node-derived B cells by deep immune reper-
toire sequencing of the Ig M heavy-chain VDJ region. The clonal diversity of
each sample was estimated by using the Shannon diversity index; a higher
Shannon index indicates a greater diversity [n = 4 mice per group (Upper, A),
n = 2 mice per group (Lower, A)].
Fig. 6. Antigen-presenting capacity of reoccurring B cells 8 and 12 wk after
anti-CD20 withdrawal. C57BL/6 mice were treated with anti-CD20 (α-CD20)
or isotype antibodies for 3 wk, followed by immunization with MOG pro-
tein1–117 (MOG1–117) or MOG peptide35–55 (MOG35–55). At the time points
indicated, B cells were isolated from spleen and cocultured with carboxy-
fluorescein succinimidyl ester (CFSE)-labeled naïve 2D2 T cells for 72 h.
According to the preceding immunization, cells were restimulated with
MOG1–117 or MOG35–55. (A) Overview of the experimental setup. Shown is the
proliferation of 2D2 T cells cocultured with B cells isolated from (B) MOG1–117-
and (C) MOG35–55-immunized mice 8 or 12 wk after the last α-CD20/isotype
treatment. T cell proliferation was assessed by flow cytometry by using CFSE
dilution. Shown is the proliferation of T cells cocultured with reoccurring B cells
(previously α-CD20–treated mice) in relation to T cells cocultured with never-
depleted B cells (isotype-treated mice). (D) Ten weeks after the last α-CD20/
control treatment, B cells were isolated from the spleen of MOG protein1–117-
immunized mice and cultured with DyLight-405–labeled MOG protein1–117
(MOG1–117-DyL405) for 2 h. Shown are representative dot plots (Left) and the
mean percentage ± SEM of MOG1–117-DyL405
+ B cells (Right) in the spleen of
α-CD20- and isotype-treated mice (n = 6–8 mice per group; **P < 0.01).
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memory B cells (24). Along the same lines, patients with rheu-
matoid arthritis exhibited relapse after anti-CD20 treatment
depending on the frequency of memory B cells within the ree-
merging B cell pool (18, 25). These findings further consolidate
that the pool of memory B cells can expand in a situation in
which the autoantigen is accessible to reemerging B cells and
that clonal expansion of antigen-activated B cells is associated
with an unfavorable outcome.
Similar to the autoimmune diseases described here earlier, B
cells replete with a predominance of CD27+ memory B cells in
patients with NMO (26), and the general reoccurrence of B cells
is associated with an immediate redevelopment of clinical ac-
tivity (27, 28). This observation suggests that pathogenic
aquaporin-4–recognizing B cells persist and possibly expand, and
that patients with NMO accordingly may need to be continuously
depleted of B cells (27). In contrast, in treatment of MS, clinical
stabilization and silencing of disease activity measured by MRI
upon anti-CD20 treatment appears to outlast the absence of B
cells (1, 20). In regard to this presumably differential outcome, a
recent investigation compared the IgG gene repertoire before
and after anti-CD20 treatment in three patients, one with NMO,
one with recurrent myelitis, and one with progressive MS (29).
Of note, this crucial pilot study detected an expansion of memory
B cells within the pool of reemerging B cells in all three patients.
Based on this preliminary finding, a relative expansion of pe-
ripheral memory B cells may occur independent of the un-
derlying disease entity, which could, however, have differential
consequences in NMO vs. MS, as in the latter disease most ev-
idence suggests that B cell pathogenicity develops by a B cell-
fostering milieu within the CNS (30).
In conclusion, our findings imply that, in the treatment of CNS
demyelinating disorders, systemic anti-CD20 should be used with
a sense of proportion. We highlight that, in principle, unselective
extinction of B cells concomitantly abolishes preexisting regulatory
B cell properties, which may be particularly important for limiting
myeloid cell activity and chronic disease progression. In regard to
its current use, our experimental study demonstrates how diverse
B cells can return after anti-CD20 treatment and highlights the
need for biomarkers assessing when, how frequently, and how long
an individual patient with MS, NMO, or other disease should
receive systemic anti-CD20 (31). Our study furthermore estab-
lishes that, in the process of repletion, emerging B cells are sus-
ceptible to modulation, giving rise to the concept that a suitable
maintenance medication could most efficiently foster regulatory B
cell properties and prevent redevelopment of pathogenic B cell
function after anti-CD20 induction therapy.
Materials and Methods
Animal experiments were carried out in accordancewith the guidelines of the
Central Department for Animal Experiments, University Medical Center,
Göttingen, and approved by the Office for Consumer Protection and Food
Safety of the State of Lower Saxony. Mice were immunized with 100 μg
MOG peptide35–55 or 75 μg MOG protein1–117, and EAE severity was assessed
daily and scored on a scale from 0 to 5. B cell depletion was achieved by
three weekly i.p. injections of 200 μg murine anti-CD20 or isotype control. At
the indicated time points, B cell frequencies were assessed by flow cytom-
etry. Detailed descriptions of study materials and methods are provided in SI
Appendix, SI Materials and Methods.
ACKNOWLEDGMENTS. We thank Katja Grondey and Julian Koch for
excellent technical support. This work was supported by the Startförderung
of the Universitätsmedizin Göttingen (D.H. and S.H.-K.); Deutsche For-
schungsgemeinschaft Grants WE 3547/5-1 (to M.S.W.), LE 3079/3-1 (to
K.L.-H.), and SFB-TR-128 (to K.L.-H.); Novartis (M.S.W.); TEVA (M.S.W.);
Biogen-Idec (M.S.W.); Roche (M.S.W.); Merck (M.S.W.); the ProFutura Pro-
gramm of Universitätsmedizin Göttingen (M.S.W.); Munich Cluster for Sys-
tems Neurology (SyNergy) (K.L.-H.); the Hertie Foundation (MyLab Program)
(K.L.-H.); and National Multiple Sclerosis Society Grant G-1508-07064
(K.L.-H.). M.S.W. is serving as an editor for PLoS One.
1. Hauser SL, et al.; HERMES Trial Group (2008) B-cell depletion with rituximab in
relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688.
2. Bar-Or A, et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: A 72-week,
open-label, phase I trial. Ann Neurol 63:395–400, and erratum (2008) 63:803.
3. Hawker K, et al.; OLYMPUS trial group (2009) Rituximab in patients with primary
progressive multiple sclerosis: Results of a randomized double-blind placebo-
controlled multicenter trial. Ann Neurol 66:460–471.
4. Stellmann JP, et al.; NEMOS (Neuromyelitis Optica Study Group) (2017) Immuno-
therapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of re-
sponse. J Neurol Neurosurg Psychiatry 88:639–647.
5. Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuro-
myelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA
Neurol 73:1342–1348.
6. Jacob A, et al. (2008) Treatment of neuromyelitis optica with rituximab: Retrospective
analysis of 25 patients. Arch Neurol 65:1443–1448.
7. Hauser SL, et al.; OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab
versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234.
8. Kappos L, et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: A phase
2, randomised, placebo-controlled, multicentre trial. Lancet 378:1779–1787.
9. Montalban X, et al.; ORATORIO Clinical Investigators (2017) Ocrelizumab versus pla-
cebo in primary progressive multiple sclerosis. N Engl J Med 376:209–220.
10. Xiao Y, Hendriks J, Langerak P, Jacobs H, Borst J (2004) CD27 is acquired by primed B
cells at the centroblast stage and promotes germinal center formation. J Immunol
172:7432–7441.
11. Clements CS, et al. (2003) The crystal structure of myelin oligodendrocyte glycopro-
tein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci USA 100:11059–11064.
12. Weber MS, et al. (2010) B-cell activation influences T-cell polarization and outcome of
anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 68:
369–383.
13. Monson NL, et al. (2011) Rituximab therapy reduces organ-specific T cell responses
and ameliorates experimental autoimmune encephalomyelitis. PLoS One 6:e17103.
14. Lehmann-Horn K, et al. (2011) Anti-CD20 B-cell depletion enhances monocyte re-
activity in neuroimmunological disorders. J Neuroinflammation 8:146.
15. Moulin V, et al. (2000) B lymphocytes regulate dendritic cell (DC) function in vivo:
Increased interleukin 12 production by DCs from B cell-deficient mice results in T
helper cell type 1 deviation. J Exp Med 192:475–482.
16. Gelfand JM, Cotter J, Klingman J, Huang EJ, Cree BA (2014) Massive CNS monocytic
infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol
Neuroimmunol Neuroinflamm 1:e34.
17. Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: Pathology
and pathogenesis. Nat Rev Neurol 8:647–656.
18. Pers JO, et al. (2008) B-cell depletion and repopulation in autoimmune diseases. Clin
Rev Allergy Immunol 34:50–55.
19. Adlowitz DG, et al. (2015) Expansion of activated peripheral blood memory B cells in
rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response.
PLoS One 10:e0128269.
20. Salzer J, et al. (2016) Rituximab in multiple sclerosis: A retrospective observational
study on safety and efficacy. Neurology 87:2074–2081.
21. Cohen M, et al. (2017) Monitoring CD27+ memory B-cells in neuromyelitis optica
spectrum disorders patients treated with rituximab: Results from a bicentric study.
J Neurol Sci 373:335–338.
22. Greenberg BM, et al. (2012) Rituximab dosing and monitoring strategies in neuro-
myelitis optica patients: Creating strategies for therapeutic success. Mult Scler 18:
1022–1026.
23. Chamberlain N, et al. (2016) Rituximab does not reset defective early B cell tolerance
checkpoints. J Clin Invest 126:282–287.
24. Maurer MA, et al. (2012) Rituximab induces sustained reduction of pathogenic B cells
in patients with peripheral nervous system autoimmunity. J Clin Invest 122:
1393–1402.
25. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of pe-
ripheral blood B cells after depletion with rituximab in patients with rheumatoid
arthritis. Arthritis Rheum 54:613–620.
26. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab
based on the assessment of peripheral circulating memory B cells in patients with
relapsing neuromyelitis optica over 2 years. Arch Neurol 68:1412–1420.
27. Pellkofer HL, et al. (2011) Long-term follow-up of patients with neuromyelitis optica
after repeated therapy with rituximab. Neurology 76:1310–1315.
28. Cassinotto C, Joux J, Chausson N, Smadja D, Cabre P (2008) [Failure of rituximab in
relapsing neuromyelitis optica: Case report with two-year prospective follow-up]. Rev
Neurol (Paris) 164:394–397.
29. Maurer MA, et al. (2016) Rituximab induces clonal expansion of IgG memory B-cells in
patients with inflammatory central nervous system demyelination. J Neuroimmunol
290:49–53.
30. Corcione A, et al. (2005) B-cell differentiation in the CNS of patients with multiple
sclerosis. Autoimmun Rev 4:549–554.
31. Hohlfeld R, Meinl E (2017) Ocrelizumab in multiple sclerosis: Markers and
mechanisms. Lancet Neurol 16:259–261.
9778 | www.pnas.org/cgi/doi/10.1073/pnas.1810470115 Häusler et al.
